Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Auclerc

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemiaG Michel, J Landman-Parker, M F Auclerc, et al.
Leukemia|September 26, 2013
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletionsE Clappier, M F Auclerc, J Rapion, et al.
Leukemia|March 27, 2004
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcomeN A Heerema, J Harbott, S Galimberti, et al.
Leukemia|October 30, 2013
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcomeC J Harrison, A V Moorman, C Schwab, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2000
Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemiaG Michel, J Landman-Parker, M F Auclerc, et al.
Leukemia|September 26, 2013
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletionsE Clappier, M F Auclerc, J Rapion, et al.
Leukemia|March 27, 2004
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcomeN A Heerema, J Harbott, S Galimberti, et al.
Leukemia|October 30, 2013
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcomeC J Harrison, A V Moorman, C Schwab, et al.
Pageof 6